FlawedByDesign
Bluelighter
- Joined
- Apr 4, 2009
- Messages
- 1,894
So I pm'd sekio and tricomb(couldn't think of the newer guy/gal's names off of the top of my head) to get the ok to make a Tianeptine megthread. All things pertaining to Tianeptine such as my Hanlding/Storing/Making a Tianeptine solution thread could be posted here.
Getting to it...
Tianeptine is an atypical tricyclic antidepressant. It's sold under the brand names such as Stablon, Coaxil, Tatinol and Tianeurax in a number of countries. As a tricyclic antidepessant it is atypical in that recent research suggests in that it affects depression through indirect alteration of glutamate receptor activity(taken from wiki).
Also from wiki:
Moar wiki:
Side effects:
Getting to it...
Tianeptine is an atypical tricyclic antidepressant. It's sold under the brand names such as Stablon, Coaxil, Tatinol and Tianeurax in a number of countries. As a tricyclic antidepessant it is atypical in that recent research suggests in that it affects depression through indirect alteration of glutamate receptor activity(taken from wiki).
Also from wiki:
It's oral half-life is supposed to be 2.5-3 hours hence the prescribed dose being 12.5mgs several times a day and the oral bioavailability is said to be 99%Tianeptine research was revolutionised in July 2014 with publication of the unexpected discovery that tianeptine is a full agonist at the μ and δ opioid receptors with negligible effect at the κ opioid receptors. Selective μ opioid agonists in the brain's "hedonic hotspots" typically induce euphoria. Selective kappa agonists typically induce dysphoria. The role of central delta opioid receptors is poorly understood. Dual activation of the mu and, less potently, the delta opioid receptors may be critical to tianeptine's mood-brightening and anxiolytic effect - a therapeutic action seemingly unaccompanied by the physiological tolerance and dependence that have plagued traditional opioids. Previous research into tianeptine may need to be re-evaluated in this light.
Moar wiki:
Tianeptine shows efficacy against serious depressive episodes (major depression), comparable to amitriptyline, imipramine and fluoxetine, but with significantly fewer side effects. It was shown to be more effective than maprotiline in a group of people with co-existing depression and anxiety. Tianeptine also displays significant anxiolytic properties and is useful in treating a spectrum of anxiety disorders including panic disorder, as evidenced by a study in which those administered 35% CO2 gas (carbogen) on paroxetine or tianeptine therapy showed equivalent panic-blocking effects. Like many antidepressants (including bupropion, the selective serotonin reuptake inhibitors, the serotonin-norepinephrine reuptake inhibitors, moclobemide and numerous others) it may also have a beneficial effect on cognition in people with depression-induced cognitive dysfunction.
Tianeptine has been found to be effective in depression in Parkinson's disease and in post-traumatic stress disorder of which it was as safe and effective as fluoxetine and moclobemide. A clinical trial has been conducted to compare its efficacy and tolerability with amitriptyline in the treatment of irritable bowel syndrome. The results of this trial showed that tianeptine was at least as effective as amitriptyline and produced less prominent adverse effects such as dry mouth and constipation.
Tianeptine has been reported to be very effective for asthma. In August 1998, Dr. Fuad Lechin and colleagues at the Central University of Venezuela Institute of Experimental Medicine in Caracas published the results of a 52-week randomized controlled trial of asthmatic children; the children in the groups that received tianeptine had a sharp decrease in clinical rating and increased lung function. Two years earlier, they had found a close, positive association between free serotonin in plasma and severity of asthma in symptomatic persons. As tianeptine was the only agent known to both reduce free serotonin in plasma and enhance uptake in platelets, they decided to use it to see if reducing free serotonin levels in plasma would help. By November 2004, there had been two double-blind placebo-controlled crossover trials and a >25,000 person open-label study lasting over seven years, all showing effectiveness. A 2005 study in Egypt demonstrated tianeptine to be effective in men with depression and erectile dysfunction. Tianeptine also has anticonvulsant and analgesic effects, and a clinical trial in Spain that ended in January 2007 has shown that tianeptine is effective in treating pain due to fibromyalgia. Tianeptine has been shown to have efficacy with minimal side effects in the treatment of attention-deficit hyperactivity disorder.
Side effects:
Compared to other TCAs it produces significantly fewer cardiovascular, anticholinergic (like dry mouth or constipation), sedative and appetite-stimulating effects. A recent review found that it was amongst the antidepressants most prone to causing hepatotoxicity (liver damage), although the evidence to support this concern was of limited quality
Last edited: